Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) — Sustainability Report | 27 August 2026
Jagsonpal Pharmaceuticals Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 to BSE and NSE on August 27, 2026, as mandated under SEBI LODR Regulation 34(2)(f). The standalone report details ESG disclosures across governance, environmental impact, social initiatives, and stakeholder engagement. It highlights zero material non-compliance, robust whistleblower mechanisms, and focus on patient safety and inclusive growth. The filing confirms adherence to National Guidelines on Responsible Business Conduct (NGRBC) principles, with no subsidiaries but an 85% stake in Aequitas Healthcare Pvt Ltd. No financial figures or performance metrics beyond operational disclosures are provided in the BRSR extract.
About Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when JAGSNPHARM files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track JAGSNPHARM — Free💡 Ask AI about this filing
📊 More JAGSNPHARM filings
- 🔴 Corporate Action — 24 August 2026 Jagsonpal Pharmaceuticals allotted 27,950 equity shares of Rs. 2 each under its 2022 Employee Stock ...
- 🔴 Financial Results — 4 August 2026 Jagsonpal Pharmaceuticals reported 9% revenue growth to Rs.82 crores and 22% net profit growth to Rs...
- Announcement — 30 July 2026 Jagsonpal Pharmaceuticals announced that the audio recording of its Q1 FY27 earnings conference call...
- 🔴 Financial Results — 22 July 2026 Jagsonpal Pharmaceuticals announced an investor conference call on July 30, 2026, to discuss Q1 FY27...
- Announcement — 17 July 2026 Jagsonpal Pharmaceuticals announced completion of its acquisition of an 85% equity stake in Aequitas...
🔥 Also filed on 27 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when JAGSNPHARM files new disclosures
Track JAGSNPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track JAGSNPHARM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd